Amryt Pharma Rory Nealon, CFO & COO
Amryt Pharma is a specialty biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases. The Company is building a diversified portfolio of commercially attractive, best-in-class, proprietary new drugs to help address some of these rare and debilitating illnesses for which there are currently no available treatments.
Diurnal Martin Whitaker, CEO
Founded in 2004, Diurnal is a UK-based, globally-focused specialty pharma company developing high quality products for the life-long treatment of chronic endocrine conditions. It is committed to addressing major unmet clinical and patient needs in hormone replacement, initially by developing and marketing products for the rare orphan diseases Congenital Adrenal Hyperplasia (CAH) and Adrenal Insufficiency (AI).
Midatech Pharma Speaker TBC
Midatech is a nanomedicine company focused on the development and commercialisation of multiple, high-value, targeted therapies for major diseases with unmet medical need. It is advancing a pipeline of novel clinical and pre-clinical product candidates based on its proprietary drug conjugate and sustained release delivery platforms with a clear focus on the key therapeutic areas of diabetes, cancer and neuroscience/ophthalmology.
NetScientific Francois Martelet, CEO
NetScientific is a biomedical and transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. NetScientific funds, develops and manages early/mid-stage healthcare technology companies sourced from strategic partnerships and relationships in USA and Europe with a primary focus on Digital health, Diagnostics and Therapeutics.